WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced the signing of an expanded Memorandum of Understanding (MOU) with LigaChem Biosciences, Inc., a leader in the development of innovative ADC therapies targeting cancer and other serious diseases. This new agreement broadens the scope of the ongoing collaboration, further accelerating the development of next generation innovative ADC therapies.

Under the terms of the expanded MOU, WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs. With WuXi XDC's cutting-edge technologies and extensive expertise, LigaChem will be well-positioned to seamlessly advance its ADC candidates from discovery through to development stages, ensuring a more streamlined and efficient process at every stage.

Furthermore, LigaChem will utilize WuXi XDC's fully integrated ADC development and manufacturing platform to support multiple ADC projects. This strategic expansion of the partnership strengthens both companies' shared mission to develop and deliver innovative ADC therapies that address critical unmet patients needs.

"We are excited to expand our partnership with WuXi XDC," stated Dr. Yong-Zu Kim, CEO and President of LCB, " WuXi XDC's expertise and comprehensive service offerings are crucial to the success of our ADC programs. This expanded partnership enables us to leverage their end-to-end capabilities, accelerating the development of next-generation ADC therapies to address the needs of patients."

Dr.Jimmy Li, CEO of WuXi XDC commented: "Today's expanded collaboration with LigaChem underscores the strength of our long-standing partnership. By leveraging our integrated service platforms across discovery, development, and manufacturing, LigaChem will be able to accelerate the development of their promising ADC candidates and streamline the development and manufacturing of their ADC projects. This collaboration reaffirms our ongoing commitment to helping our clients bring innovative therapies to market faster and more efficiently."

This expanded MOU builds on the initial collaboration between WuXi XDC and LigaChem, which began in 2021. Since then, both companies have made significant strides in advancing the innovation of ADCs and bioconjugates. This new agreement further solidifies the shared vision of advancing the next wave of innovation in the ADC field, poised to deliver meaningful benefits to patients worldwide.

About LigaChem Biosciences

LigaChem Biosciences is dedicated to the discovery and development of innovative therapies that leverage the power of antibody-drug conjugates to treat cancer and other serious diseases. Our mission is to improve the quality of life for patients by providing effective and targeted treatment options. For more information, please visit www.ligachembio.com

About WuXi XDC

WuXi XDC Cayman Inc.  ("WuXi XDC", stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: wuxixdc.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

TAIPEI, July 7, 2026 /PRNewswire/ -- Sports technology innovator VITBIO has announced the launch of OmniGmot AI Golfer, the world's first integrated golf biomechanics system to combine full-body AI motion capture with comprehensive plantar pressure analysis in a single wearable solution. Developed entirely with VITBIO's proprietary patented technologies, the system delivers laboratory-grade biomechanics insights directly on the golf course.

To showcase its real-world performance, VITBIO will welcome Spanish professional golfer Juan Salama, a former No. 1 ranked golfer in Spain, for live demonstrations during SPORTEC Tokyo from July 8–10 at Tokyo Big Sight. Salama will demonstrate how OmniGmot AI Golfer enables elite players to rapidly adapt to unfamiliar courses, optimize swing mechanics, and improve competitive performance using real-time AI-driven analysis.

Traditionally, golfers have relied on separate indoor motion capture systems and stationary force plates, making comprehensive biomechanics analysis impractical during actual play. OmniGmot AI Golfer eliminates this limitation by seamlessly integrating wearable AI smart insoles with full-body motion sensing, synchronizing ground reaction force, movement patterns, and swing mechanics through VITBIO's proprietary AI algorithms.

The system has been recognized by the Global Sports Innovation Center (GSIC), powered by Microsoft, and received the prestigious 2025 ISPO Product & Service Award, highlighting its innovation and impact on sports technology.

"OmniGmot AI Golfer gives my coach and me a completely new level of performance insight," said Juan Salama. "By combining foot pressure, movement patterns, and full-body motion analysis in real time, we can quickly understand how subtle weight shifts influence ball contact and make immediate adjustments when competing on unfamiliar courses."

Key innovations include:

• The world's first integrated AI system combining full-body motion capture with dynamic plantar pressure tracking.
• Outdoor-ready wearable technology that delivers accurate biomechanics data in real playing conditions.
• AI-powered pre-round analysis that builds a course-specific swing optimization model within minutes, helping golfers adapt quickly before competition.

VITBIO's integrated AI platform represents a significant advancement in wearable sports biomechanics and has already been invited for technical evaluation in international professional tournaments.

Visit VITBIO at Booth E1-6-5 during SPORTEC Tokyo, July 8–10, to experience the next generation of AI-powered golf performance technology.

About VITBIO

VITBIO is a pioneer in wearable sports technology, specializing in AI-powered biomechanics solutions developed through proprietary patented innovations. The company is dedicated to advancing athletic performance with intelligent wearable technologies that empower golfers and athletes worldwide.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

VITBIO Unveils the World's First AI Golf Training System Combining Full-Body Motion Capture and Plantar Pressure Analysis